# Daniel J. Lenihan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/daniel-j-lenihan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,435 |
| Field | Chemotherapy-induced cardiotoxicity and mitigation |
| h-index | 64 |
| i10-index | 173 |
| Last Known Institution | Saint Francis Medical Center |
| OpenAlex ID | https://openalex.org/A5045593578 |
| ORCID iD | https://orcid.org/0000-0001-9458-0154 |
| Works | 443 |

## Researcher papers

- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://scholariq.org/papers/2022-esc-guidelines-on-cardio-oncology-developed-in-collaboration-with-the-2/)
- [Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations](https://scholariq.org/papers/management-of-cardiac-disease-in-cancer-patients-throughout-oncological/)
- [Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association](https://scholariq.org/papers/current-diagnostic-and-treatment-strategies-for-specific-dilated/)
- [Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society](https://scholariq.org/papers/baseline-cardiovascular-risk-assessment-in-cancer-patients-scheduled-to-receive/)
- [Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement](https://scholariq.org/papers/defining-cardiovascular-toxicities-of-cancer-therapies-an-international-cardio/)
- [Genotype and Phenotype of Transthyretin Cardiac Amyloidosis](https://scholariq.org/papers/genotype-and-phenotype-of-transthyretin-cardiac-amyloidosis/)
- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://scholariq.org/papers/2022-esc-guidelines-on-cardio-oncology-developed-in-collaboration-with-the/)
- [Validation and Potential Mechanisms of Red Cell Distribution Width as a Prognostic Marker in Heart Failure](https://scholariq.org/papers/validation-and-potential-mechanisms-of-red-cell-distribution-width-as-a/)

## Researcher topics

- [Chemotherapy-induced cardiotoxicity and mitigation](https://scholariq.org/topics/chemotherapy-induced-cardiotoxicity-and-mitigation/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Amyloidosis: Diagnosis, Treatment, Outcomes](https://scholariq.org/topics/amyloidosis-diagnosis-treatment-outcomes/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)

## Researcher university

- [Saint Francis Medical Center](https://scholariq.org/institutions/saint-francis-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.